Cannabidiol (CBD), a non-psychoactive cannabinoid, is efficacious as an adjunctive treatment in children with epilepsy associated with Dravet (DS) and Lennox-Gastaut syndromes (LGS)[8,35,36,37,38,39]. Thus, the FDA [34], EMA [40] and NICE [41,42] have licensed highly purified CBD (Epidyolex® or Epidiolex®), with the EMA and NICE specifying this as an option for adjuvant therapy with clobazam in the treatment of DS/LGS. Interactions may influence the efficacy or concentration of medications at their sites of action as well as contribute to side effects and adverse events.
4
OCT
OCT
0